Search

A potential hazard associated with ferrochrome production is the unintentional generation of Cr(VI) in the off-gas dusts produced during smelting. Cr(VI) is a well-known environmental toxin and genotoxic carcinogen. Although Cr(VI) has been identified in baghouse dusts associated with submerged-arc furnaces, its occurrence in DC-arc-furnace dusts has not been previously investigated. In this study, we report the bulk composition and phase make-up, as well as the surface and bulk speciation of Cr and Fe of dusts generated during smelting of chromite ore under basic slag conditions in a pilot-scale DC arc smelter. Dusts are captured from both within the DC furnace as well as along the off-gas handling stream, after passing through the afterburner. The dusts primarily comprise feed material (chromite, flux, reductant), aerosolized slag, and glassy spherules, interpreted as off-gas condensates. Dusts collected from within the furnace, known as freeboard dusts, are dominated by feed materials, with elevated amounts of flux (lime) and lesser amounts of slag and spherules. In contrast, spherules dominate dusts collected along the off-gas handling stream by dust separators that capture the increasingly fine-grained fraction of dust, with the highest proportion of spherules occurring in baghouse dusts. Chromite is the primary host of Cr in all dust samples, whereas the spherules have low Cr contents. Cr(VI) was identified by X-ray photoelectron spectroscopy in the surfaces of dust collected from all parts of the smelter system considered, including from the furnace freeboard, despite the overall reducing conditions present therein. Cr(VI) concentrations are sufficiently high in dusts collected from the off-gas handling stream (post-afterburner, cyclone, and baghouse) to be detected in the bulk dust samples by X-ray absorption spectroscopy. The higher concentration of Cr(VI) in the finer-grained off-gas dusts, especially the baghouse dusts, is consistent with the increased abundance of spherules, the major Cr(VI)-hosting phase, in these samples. Fe is similarly more oxidized in dusts collected down the off-gas handling stream compared to dusts collected from within the furnace, which are dominated by Fe(II). Fe(III) hosted by FeOOH is predominate in dusts collected from all locations along the off-gas handling stream. These results demonstrate that there is sufficient oxygen ingress and sufficiently high temperatures in the closed DC furnace for Cr(VI) to be generated in the freeboard off-gas dusts. Cr(VI) is associated with the finest grained fraction of dusts, underlining the importance of ensuring the continual improvement of dust-capture systems, especially in terms of their ability to target increasingly finer fractions of dust.

Background: Treatment of sickle cell anemia is a challenging task and despite the well understood genetic and biochemical pathway of sickle hemoglobin, current therapy continues to be limited to the symptomatic treatment of pain, supplemental oxygen, antibiotics, red blood cell transfusions and hydroxyurea. SANGUINATE is a carbon monoxide releasing molecule and oxygen transfer agent under clinical development for the treatment of sickle cell anemia and comorbidities., Methods: An open-label randomized Phase Ib study was performed in adult sickle cell anemia patients. Two dose levels of SANGUINATE were compared to hydroxyurea in 24 homozygotes for Hb SS. Twelve subjects received either a low dose (160mg/kg) of SANGUINATE or 15mg/kg hydroxyurea. Another 12 subjects received either a high dose (320mg/kg) of SANGUINATE or 15mg/kg hydroxyurea. The primary endpoint was the safety of SANGUINATE versus hydroxyurea in sickle cell anemia patients. Secondary endpoints included determination of the plasma pharmacokinetics and assessment of hematologic measurements., Results: Musculoskeletal related adverse events were the most common. Transient troponin I levels increased in three patients, one of whom had an increase in tricuspid regurgitant velocity; however, no clinical signs were noted. Following an assessment of vital signs, tricuspid regurgitant velocity, electrocardiogram, serum biochemistry, hematology, urinalysis, and analysis of reported adverse events, SANGUINATE was found to be safe in stable sickle cell anemia patients., Conclusions: The clinical trial met its primary objective of demonstrating an acceptable safety profile for SANGUINATE in patients with sickle cell anemia. This trial established the safety of SANGUINATE at both dose levels and permitted its advance to Phase II trials., (Copyright © 2016 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. All rights reserved.)

Recent developments in behavior therapy for persons with developmental disabilities and behavior disorders emphasize positive treatment designs that focus on understanding the causes of behavior, teaching functional alternatives, and enhancing the quality of daily experiences, rather than simple contingency management. There is little information on how well direct care staff can support these nonaversive strategies. This study examined the effects of training in traditional (positive) behavior management versus nonaversive principles on the understanding and attitudes of direct care staff. Overall, nonprofessional level staff receiving the nonaversive training showed increased sophistication in understanding the range of possible causes of behavior and were able to generate treatment suggestions based on skill development and environmental change. The effectiveness of staff in implementing state-of-the-art behavior therapy procedures is likely to be an important component of the continued success of behavior therapy, especially in residential settings, both institutional and community-based.